Gilead Sciences

Despite uncertainties in the effectiveness of treatment with Remdesivir, the European Commission has secured from US-based Gilead 30,000 doses on a €63 million contract.
Remdesivir is the first drug to be approved in the European Union for the treatment of Covid-19.

Biopharmaceutical company Gilead Sciences Inc. announced that trials for its inhaled solution of Remdesivir have begun. The randomised, placebo-controlled trial will be tested on 60 healthy patients between the ages of 18-45 to determine the safety, tolerability and pharmacokinetics of the drug.

"With promising data emerging from the randomized, clinical trials of intravenous remdesivir administered to hospitalized patients, it became clear that efforts were needed to investigate the drug’s potential in the outpatient setting. Significant research efforts have been undertaken to deliver remdesivir in an inhaled, nebulized format," so Chief Medical Officer Dr. Merdad Parsey.